ArticleFrontiers in microbiology2022
Prevalence and distribution of extended-spectrum β-lactamase and AmpC-producing
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Linking land use to the likely origins of third-generation cephalosporin-resistant Enterobacterales in freshwater.Applied and environmental microbiology · 2026Article
- Genotypic Profiling of Virulence and Antibiotic Resistance Genes ofInternational journal of microbiology · 2026Article
- Prevalence of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Fecal carriage of resistant Escherichia coli in livestock in Algeria: emergence of NDM and OXA-181.BMC microbiology · 2025Article
- Molecular characterization of multidrug-resistant Escherichia coli in the Greater Accra Region, Ghana: a 'One Health' approach.One health outlook · 2025Article
- Assessing antimicrobial resistance in pasture-based dairy farms: a 15-month surveillance study in New Zealand.Applied and environmental microbiology · 2024Article
- Impact of systemic antimicrobial therapy on the faecal microbiome in symptomatic dairy cows.PloS one · 2024Article
- Prevalence and Risk Factors of β-Lactamase Genes of Extended-Spectrum β-Lactamases-ProducingEnvironmental health insights · 2024Article
- The fly route of extended-spectrum-β-lactamase-producingFrontiers in antibiotics · 2024Article
- Molecular identification ofJournal of veterinary research · 2023Article
- Editorial: Infectious diseases, microbial ecology, and antimicrobial resistance dynamics in food animals.Frontiers in veterinary science · 2023Article
- Characterization of cephalosporin and fluoroquinolone resistant Enterobacterales from Irish farm waste by whole genome sequencing.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is a global threat to human and animal health, with the misuse and overuse of antimicrobials being suggested as the main driver of resistance. In a global context, New Zealand (NZ) is a relatively low user of antimicrobials in animal production. However, the role antimicrobial usage on pasture-based dairy farms, such as those in NZ, plays in driving the spread of AMR within the dairy farm environment remains equivocal. Culture-based methods were used to determine the prevalence and distribution of extended-spectrum β-lactamase (ESBL)- and AmpC-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.